Please assess the completion status of the following clinical trial:

Trial Title: Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* HIV RNA greater than or equal to 1000 c/mL.~* Failed/Failing protease inhibitor based antiretroviral therapy.~* Stable antiretroviral therapy for greater than or equal to 30 days prior to screening.~* Negative Serum Pregnancy Test.~* GFR by Cockcroft Gault greater than or equal to 80 mL/min.~* AST \& ALT less than or equal to 2.5x ULN.~* Total Bilirubin less than or equal to 1.5 mg/dL.~* Albumin greater than 3.5 mg/dL.~* Prothrombin Time INR 1.0-1.4~* Platelets greater than or equal to 50,000.~* Hemoglobin greater than or equal to 8.0 mg/dL.~* Absolute Neutrophil Count greater than or equal to 1000.~Exclusion Criteria:~* New AIDS defining condition within 30 days of baseline.~* Prior treatment with HIV-1 integrase inhibitor (except patients from 183-101).~* Ascites or encephalopathy.~* Breast Feeding.~* Cancer Diagnosis (besides Kaposi Sarcoma or Basal Cell Carcinoma).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).